Clinical differences among the aromatase inhibitors

Clinical Cancer Research

Volumn 9, Issue 1 II, 2003, Pages

  Ligibel, Jennifer A ^a   Winer, Eric P ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE INHIBITOR; ESTROGEN RECEPTOR; EXEMESTANE; HYDROCORTISONE; LETROZOLE; MEGESTROL ACETATE; PROGESTERONE RECEPTOR; TAMOXIFEN; TETRACOSACTIDE; VOROZOLE;

ALOPECIA; ASTHENIA; BREAST CANCER; CANCER GROWTH; CANCER MORTALITY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG METABOLISM; DRUG STRUCTURE; DRUG TOLERABILITY; ENZYME INHIBITION; HOT FLUSH; HUMAN; METASTASIS; NAUSEA; POSTMENOPAUSE; PRIORITY JOURNAL; THROMBOEMBOLISM; WEIGHT GAIN;

ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; ENZYME INHIBITORS; FEMALE; HUMANS; SALVAGE THERAPY;

EID: 0037240179     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (30)

1. Sunderland, M. and Osborne, C. Tamoxifen in premenopausal patients with metastatic breast cancer: a review. J. Clin. Oncol., 9: 1283-1297, 1991.
2. Early Breast Cancer Trialists' Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet, 351: 1451-1467, 1998.
3. Geisler, J., Haynes, B., Anker, G., Dowsett, M., and Lonning, P. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J. Clin. Oncol., 20: 751-757, 2002.
4. Lamb, H. and Adkins, J. Letrozole. A review of its use in postmenopausal women with advanced breast cancer. Drugs, 56: 1125-1140, 1998.
5. Howell, A., Downey, S., and Anderson, E. New endocrine therapies for breast cancer. Eur. J. Cancer, 32A: 576-588, 1996.
6. Jonat, W., Howell, A., Blomquist, C., Eiermann, W., Winblad, G., Tyrell, C., Mauriac, L., Roche, H., Lundgren, S., Hellmund, R., and Azab, M. A randomized trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patient with advanced breast cancer. Eur. J. Cancer, 32A: 404-412, 1996.
7. Dombernowsky, P., Smith, I., Falkson, G., Leonard, R., Panasci, L., Bellmunt, J., Bezwada, W., Gardin, G., Gudgeon, A., Morgan, M., Fornasiero, A., Hoffman, W., Michel, J., Hatschek, T., Tjabbes, T., Chaudri, H., Hornberger, U., and Trunet, P. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J. Clin. Oncol., 16: 453-461, 1998.
8. Kaufmann, M., Bajetta, E., Dirix, L. Y., Fein, L. E., Jones, S. E., Zilembo, N., Dugardyn, J. L., Nasurdi, C., Mennel, R. G., Cervek, J., Fowst, C., Polli, A., di Salle, E., Arkhipov, A., Piscitelli, G., Miller, L. L., and Massimini, G. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a Phase III randomized double-blind trial. J. Clin. Oncol., 18: 1399-1411, 2000.
9. Buzdar, A., Jonat, W., Howell, A., Jones, S., Blomquist, C., Vogel, C., Eiermann, W., Wolter, J., Azab, M., Webster, A., and Plourde, P. Anastrozole, a potent and selective aromatase inhibitor versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two Phase III trials. J. Clin. Oncol., 14: 2000-2011, 1996.
10. Buzdar, A., Jones, S., Vogel, C., and Wolter, J. A. Phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Cancer (Phila.), 79: 730-739, 1997.
11. Buzdar, A., Douma, J., Davidson, N., Elledge, R., Morgan, M., Smith, R., Porter, L., Nabholtz, J., Xiang, X., and Brady, C. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J. Clin. Oncol., 19: 3357-3366, 2001.
12. Messori, A., Cattel, F., Trippoli, S., and Vaiani, M. Survival in patients with metastatic breast cancer: analysis of randomized studies comparing oral aromatase inhibitors versus megestrol. Anticancer Drugs, 11: 701-706, 2000.
13. Nabholtz, J., Buzdar. A., Pollak, M., Harwin, W., Burton, G., Mangalik, A., Steinberg, M., Webster, A., and von Euler, M. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. J. Clin. Oncol., 18: 3758-3767, 2000.
14. Bonneterre, J., Robertson, J., Thurlimann, B., Krzakowski, M., and Mauriac, L. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the (TARGET) tamoxifen or arimidex randomized group efficacy and tolerability study. J. Clin. Oncol., 18: 3748-3757, 2000.
15. Milla-Santos, A., Milla, L., Raool, L., and Solano, V. Phase III trial of anastrozole vs. tamoxifen in postmenopausal patients with hormone-dependent advanced breast cancer (abstract). Eur. J. Cancer, 37 (Suppl. 5): 4, 2001.
16. Mouridsen, H., Gershanovich, M., Sun, Y., Perez-Carrion, R., Boni, C., Monnier, A., Apffelstaedt, J., Smith, R., Sleeboom, H., Janicke, F., Pluzanska, A., Dank, M., Becquart, D., Bapsy, P., Salminen, E., Snyder, R., Lassus, M., Verbeek, J., Staffler, B., Chaudri-Ross, H., and Dugan, M. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a Phase III study of the International Letrozole Breast Cancer Group. J. Clin. Oncol., 19: 2596-2606, 2001.
17. Bonneterre, J., Buzdar, A., Robertson, J., Thurlimann, B., von Euler, M., Sahmoud, T., Webster, A., and Steinberg, M. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer (Phila.), 92: 2247-2258, 2001.
18. Dirix, L., Piccart, M., Lohrish, C., Beex, L., Nooij, M., Cameron, D., Biganzoli, T., Cufer, T., Yague, C., Duchateau, L., Lobelle, J., and Paridaens, R. Efficacy of and tolerance to exemestane versus tamoxifen in first-line hormone therapy of postmenopausal metastatic breast cancer patients: a European Organization for the Research and Treatment of Cancer (EORTC Breast Group) Phase II trial with Pharmacia and Upjohn. Proc. Am. Soc. Clin. Oncol., abstract 114, 2001.
19. Boccardo, F., Rubagotti, A., Amoroso, D., Mesiti, M., Romeo, D., and Caroti, C. Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: results of an Italian Cooperative Study. J. Clin. Oncol., 19: 4209-4215, 2001.
20. Baum, M. The ATAC (Arimidex or Tamoxifen Alone or in Combination) adjuvant breast cancer trial in postmenopausal women. Breast Cancer Res. Treat., 69: 210, 2001.
21. The ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359: 2131-2139, 2002.
22. Winer, E., Hudis, C., Burstein, H., Chlebowski, R., Ingle, J., and Edge, S. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. J. Clin. Oncol., 20: 3317-3327, 2002.
23. Ellis, M., Coop, A., Singh, B., Mauriac, L., Llombert-Cussac, A., and Janicke, F. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1 and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a Phase III randomized trial. J. Clin. Oncol., 19: 3808-3816, 2001.
24. Gershanovich, M., Chaudri, H., and Campos, D. Letrozole, a new oral aromatase inhibitor: randomized trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Ann. Oncol., 9: 639-645, 1998.
25. Yates, R., Dowsett, M., Fisher, G., Selen, A., and Wyld, P. Arimidex (ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers. Br. J. Cancer, 75: 543-548, 1996.
26. Wolter, J., Robert, N., Harvery, H., and Berkowitz, I. "Arimidex" (ZD1033): a Phase I study of a new, selective orally active aromatase inhibitor in postmenopausal women with advanced breast cancer. Proc. Am. Soc. Clin. Oncol., abstract 119, 1995.
27. Bajetta, E., Zilembo, N., Dowsett, M., Guillevin, L., DiLeo, A., Celio, L., Martin, A., Marchiano, A., Pozzi, P., Stani, S., and Bichisao, E. Double-blind, randomized, multicenter endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients. Eur. J. Cancer, 35: 208-213, 1999.
28. Bisagni, G., Cocconi, G., Scaglione, F., Fraschini, F., and Pfister, C. Letrozole, a new oral non-steroidal aromatase inhibitor in treating postmenopausal patients with advanced breast cancer. A pilot study. Ann. Oncol., 7: 99-102, 1996.
29. Buzdar, A. and Howell, A. Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer. Clin. Cancer Res., 7: 2620-2635, 2001.
30. Rose, C., Vtoraya, O. A. P., Neave, F., Clemens, M., Chaudri-Ross, H., Wyld, P., and Lang, R. Letrozole (Femara) vs. anastrozole (Arimidex): second-line treatment in postmenopausal women with advanced breast cancer. Proc. Am. Soc. Clin. Oncol., abstract 131, 2002.